Actuate Therapeutics Upgraded to 'Hold' by Wall Street Zen

Got story updates? Submit your updates here. ›

Wall Street Zen, an investment research firm, has upgraded its rating on Actuate Therapeutics (NASDAQ: ACTU) from 'sell' to 'hold', citing a more balanced outlook for the company's prospects. Actuate is a clinical-stage oncology company focused on developing targeted therapies for difficult-to-treat cancers.

Why it matters

The rating change reflects Wall Street Zen's assessment that Actuate's stock, which has declined significantly over the past year, may have limited further downside at current levels. However, the 'hold' rating suggests analysts see only modest upside potential, indicating ongoing challenges for the company's drug development efforts.

The details

In its report, Wall Street Zen noted that Actuate's lead asset, atuveciclib, is currently in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors. The analysts believe the drug has potential, but face significant competition and development hurdles. The firm's previous 'sell' rating had been based on concerns about Actuate's financial position and the competitive landscape for its pipeline.

• Wall Street Zen issued its rating upgrade on Saturday, April 4, 2026.
• Actuate Therapeutics reported its most recent quarterly earnings on Thursday, March 26, 2026.

What’s next

Investors will be closely watching Actuate Therapeutics' progress with its lead drug candidate, atuveciclib, as it continues its Phase 1 clinical trial. Any updates on the drug's development timeline and potential regulatory milestones will be key to determining the company's future prospects.